{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:04:31Z","timestamp":1780563871070,"version":"3.54.1"},"reference-count":12,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>While oxaliplatin-induced peripheral neuropathy (OIPN) is more common and severe in patients who receive the previous standard, 6-month oxaliplatin-based treatment, we hypothesized that OIPN was still pervasive in patients who received shorter, 3-month-treatment regimens. Using six EORTC QLQ-CIPN20 questions that quantify numbness (N), tingling (T) and shooting\/burning pain (P) in upper\/lower distal extremities, our aim is to quantify patient-reported responses over 3 months (6 cycles) of oxaliplatin regarding symptom-specific timing, location and severity. For each question, patients were asked how each of the sensory symptoms had affected them during the preceding week, with 1 = \u201cNot at all\u201d, 2 = \u201cA little\u201d, 3 = \u201cQuite a bit\u201d and 4 = \u201cVery much\u201d. The proportional odds model for the cumulative log odds of response that allowed symptom-specific patient heterogeneity to be obtained was applied to a pooled dataset from the placebo arms of two multisite OIPN prevention trials and fit separately to the upper\/lower distal extremities. For each symptom, we report the cycle-specific marginal probabilities for each response. In 141 patients, substantial patient heterogeneity in the likelihood, at a given cycle, of a more severe response for a symptom was present. Distinct patterns in the probabilities for each response over time for N and T were observed between the upper\/lower distal extremities, while the probabilities of a response &gt;1 for P was largely negligible in both locations. Despite the decrease in exposure to oxaliplatin from 6 to 3 months, OIPN was still pervasive with patients experiencing considerable N and T in the fingers (or hands) and toes (or feet).<\/jats:p>","DOI":"10.3390\/cancers14051212","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T20:46:17Z","timestamp":1645994777000},"page":"1212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months"],"prefix":"10.3390","volume":"14","author":[{"given":"David","family":"Zahrieh","sequence":"first","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-714X","authenticated-orcid":false,"given":"Daniel","family":"Satele","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M. Lavoie","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Acute, Chronic, and Continuing Care, University of Alabama at Birmingham School of Nursing, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5752","authenticated-orcid":false,"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-7430","authenticated-orcid":false,"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00520-014-2242-z","article-title":"A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"22","author":"Beijers","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S1470-2045(18)30093-7","article-title":"3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): An international, randomised, phase 3, non-inferiority trial","volume":"19","author":"Iveson","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11888-013-0181-6","article-title":"The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status","volume":"9","author":"Andre","year":"2013","journal-title":"Curr. Colorectal Cancer Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of Adjuvant Chemotherapy for Stage III Colon Cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","article-title":"Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance)","volume":"32","author":"Loprinzi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00520-015-2876-5","article-title":"MC11C4: A pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy","volume":"24","author":"Zimmerman","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00520-011-1141-9","article-title":"The relationship between numbness, tingling, and shooting\/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA","volume":"20","author":"Wolf","year":"2012","journal-title":"Support. Care Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rubin, D.B. (1987). Multiple Imputation for Survey Nonresponse, Wiley.","DOI":"10.1002\/9780470316696"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1188\/10.CJON.E22-E28","article-title":"Patient perceptions associated with chemotherapy-induced peripheral neuropathy","volume":"14","author":"Tofthagen","year":"2010","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1188\/11.CJON.182-188","article-title":"Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin","volume":"15","author":"Tofthagen","year":"2011","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/5\/1212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:27:50Z","timestamp":1760135270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/5\/1212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14051212"],"URL":"https:\/\/doi.org\/10.3390\/cancers14051212","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}